Literature DB >> 30228662

The Opioid Crisis in Missouri: A Call to Action for Physicians, Legislators, and Society.

Lawrence Lewis1, Christopher R Carpenter2, Evan S Schwarz3, Randall S Jotte4, Corey Waller5, Rachel Winograd6, Randall Williams7, Steven Stenger8, Holly Rehder9, Shannon Governick10, Luis Giuffra11.   

Abstract

Opioid overdose deaths in the United States increased sharply over the last decade leading the President to declare a national emergency. The neurobiology of opioid addiction is explored in conjunction with the historical events preceding the current epidemic. A patient-centric perspective is provided along with rationale for contemporary Medical Assisted Therapy (MAT) options to safely reduce overdose deaths and other preventable consequences of prescription misuse and heroin abuse. A multidisciplinary medical provider approach is essential, in addition to legislative efforts to reduce current regulatory burdens that reduce access to MAT in many settings. This review introduces a new Missouri Medicine series intended to explore key concepts to simultaneously reduce opioid prescribing, while effectively managing acute and chronic pain across complex healthcare settings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 30228662      PMCID: PMC6139975     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  25 in total

1.  State prescription drug monitoring programs and fatal drug overdoses.

Authors:  Young Hee Nam; Dennis G Shea; Yunfeng Shi; John R Moran
Journal:  Am J Manag Care       Date:  2017-05       Impact factor: 2.229

Review 2.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

3.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.

Authors:  Judith I Tsui; Jennifer L Evans; Paula J Lum; Judith A Hahn; Kimberly Page
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

Review 4.  Buprenorphine use: the international experience.

Authors:  Maria Patrizia Carrieri; Leslie Amass; Gregory M Lucas; David Vlahov; Alex Wodak; George E Woody
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

5.  Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Authors:  George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

6.  Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database.

Authors:  Theodore J Cicero; Gordon Wong; Yuhong Tian; Michael Lynskey; Alexandre Todorov; Keith Isenberg
Journal:  Pain       Date:  2009-04-10       Impact factor: 6.961

Review 7.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Combatting the opioid epidemic: Baltimore's experience and lessons learned.

Authors:  Leana S Wen; Katherine E Warren
Journal:  J Public Health (Oxf)       Date:  2018-06-01       Impact factor: 2.341

Review 9.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

Authors:  Georgina J MacArthur; Eva van Velzen; Norah Palmateer; Jo Kimber; Anastasia Pharris; Vivian Hope; Avril Taylor; Kirsty Roy; Esther Aspinall; David Goldberg; Tim Rhodes; Dagmar Hedrich; Mika Salminen; Matthew Hickman; Sharon J Hutchinson
Journal:  Int J Drug Policy       Date:  2013-08-21

Review 10.  The North American opioid epidemic: current challenges and a call for treatment as prevention.

Authors:  Devesh Vashishtha; Maria Luisa Mittal; Daniel Werb
Journal:  Harm Reduct J       Date:  2017-05-12
View more
  3 in total

1.  Medications for Opioid Use Disorder: A Guide for Physicians.

Authors:  Naazia Azhar; Ravikumar Chockalingam; Asad Azhar
Journal:  Mo Med       Date:  2020 Jan-Feb

2.  Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil.

Authors:  Aida Mohammadkhani; Jennifer E Fragale; Caroline B Pantazis; Hannah E Bowrey; Morgan H James; Gary Aston-Jones
Journal:  J Neurosci       Date:  2019-10-22       Impact factor: 6.167

Review 3.  Opioid Use Disorder Assessment Tools and Drug Screening.

Authors:  James Ducharme; Sean Moore
Journal:  Mo Med       Date:  2019 Jul-Aug
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.